OBSEENATIONAL STUDIES:

Alzheimer’s Disease Neuroimaging Study (ADNI3)

- 55-90 years of age
- Normal cognition with or without subjective memory complaints, Mild Cognitive Impairment, or Alzheimer’s Disease
- Involves yearly cognitive testing, neuroimaging, and lumbar punctures

To learn more about the ADNI3 study, please contact Celine Ossinalde at 310-794-6191 or by email at cossinalde@mednet.ucla.edu. (PI: Maryam Beigi, MD)

Alzheimer’s Disease Research Center - Biomarkers in Neurodegenerative Disease (ADRC-BIND)

- 18 Years and older
- Mild Cognitive Impairment, Alzheimer’s Disease, Frontotemporal Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Dementia with Lewy Bodies, Parkinson’s Disease Dementia, Transient Epileptic Amnesia, Adult-onset Epilepsy, or Cognitively Normal
- Involves yearly cognitive testing, blood work, neuroimaging, and overnight sleep study

To learn more about the ADRC-BIND study, please contact Aisha Mohammed at 310-794-6039 or by email at AMohammed@mednet.ucla.edu. (PI: Keith Vossel, MD, MSc)

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

- 18 Years and older
- Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease), Primary Progressive Aphasia, Progressive Supranuclear Palsy, or Corticobasal Degeneration, or are from a family with a mutation linked to these disorders or significant familial history of these disorders
- Involves cognitive testing, blood work, and neuroimaging; one visit or annual

To learn more about the ALLFTD study, please contact Diana Chavez by email at DianaChavez@mednet.ucla.edu. (PI: Mario Mendez, MD, PhD)

Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID)

- 18 Years and older
- Mild Cognitive Impairment, Mild Dementia, or Cognitively Normal
- Involves yearly cognitive testing, blood work, and MRI

To learn more about the MarkVCID study, please contact Aisha Mohammed at 310-794-6039 or by email at AMohammed@mednet.ucla.edu. (PIs: Jason Hinman, MD, and Keith Vossel, MD, MSc)

Please visit our website at www.EastonAD.ucla.edu

Protocol ID:IRB#10-001189    UCLA IRB Approved   Approval Date: 2/16/2022   Committee: Medical IRB 3
Current Research Studies
Mary S. Easton Center for Alzheimer’s Disease Research at UCLA
For more information please call 310-794-6191

INTERVENTIONAL STUDIES:

Autonomy Study
Phase 2 Anti-tau Monoclonal Antibody
- 50-80 Years old, inclusive
- Mild Cognitive Impairment or early Alzheimer’s Disease
- Minimum of 5 years formal education
- Stable on neurological medications for two months
- Involves intravenous infusion every 4 weeks

To learn more about the Autonomy study, please contact Celine Ossinalde at 310-794-6191 or by email at cossinalde@mednet.ucla.edu. (PI: Maryam Beigi, MD)

Please visit our website at www.EastonAD.ucla.edu